|
|
|
Sunday, February 27, 2011 — 1:30 PM, CC 008 A/B
|
- Recent Advances in Tumors of Soft Tissue and Bone
|
|
Moderator:
|
Christopher D.M. Fletcher, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA
|
|
|
Disclosure:
|
In accordance with ACCME guidelines regarding disclosure, the USCAP policy requires that faculty members who have a significant financial or other relationship with a commercial company, entity, or service (which will be discussed in this Symposium) must disclose this to attendees. The Academy also requires that speakers disclose any products that are not labeled for the use under discussion. The speakers listed below have indicated they have nothing to disclose.
|
Click the button above to add this event to your Itinerary Planner...
 Click here to view (or print) handout in single page format for the entire meeting.
Note: Any slides will be printed in color.
Click here to view (or print) black and white handout for the entire meeting
Note: Text will be in single page format and any slides will be in 6-per-page format.
Click any blue title below to display and print the handout for individual lecture(s):
| 1:30 |
Myoepithelial Tumors of Soft Tissue and Bone - Cristina Antonescu, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 2:00 |
PEComa – An Update - Cyril Fisher, Royal Marsden Hospital, London, UK |
| 2:30 |
Other "New Entities" in Soft Tissue - Angelo P. Dei Tos, General Hospital of Treviso, Treviso, Italy |
| 3:00 |
Break |
| 3:30 |
Notochordal Tumors of Bone – What's New? - G. Petur Nielsen, Massachusetts General Hospital, Boston, MA |
| 4:00 |
Fibrous Tumors of Infancy and Childhood - An Update - Cheryl M. Coffin, Vanderbilt University Medical Center, Nashville, TN |
| 4:30 |
New Therapeutic Targets in Soft Tissue Sarcomas - Alexander J. Lazar, Anderson Cancer Center, Houston, TX |
|
The theme and content of the meeting were chosen and approved by the Society’s officers, taking into account the need to pick a novel theme of both utility and interest to general surgical pathologists as well as subspecialists interested in soft tissue and bone tumors. In recent years, new diagnostic "entities" (of sufficient frequency to be relevant to generalists) have continued to be recognized, many of which have also been found to harbor distinct genetic "signatures" which bring biologic insight. This companion meeting will seek to provide a 'state of the art' overview of these newer lesions so as to facilitate their wider and accurate recognition. The program will also provide important information regarding the molecular genetic findings in these tumors as well as the increasing characterization of "drugable" targets in soft tissue sarcomas, identification of which in tissue specimens most often falls to pathologists. |
|
|
|
